222 GSK Annual Report 2018 Notes to the company balance sheet UK GAAP including FRS 101 Reduced Disclosure Framework continued J Provisions for liabilities 2018 2017 m m At 1 January 27 23 Exchange adjustments 2 3 Charge for the year 16 52 Utilised 29 45 At 31 December 16 27 The provisions relate to a number of legal and other disputes in which the company is currently involved.
K Other non-current liabilities 2018 2017 m m Contingent consideration payable 282 238 282 238 The contingent consideration relates to the amount payable for the acquisition in 2015 of the Novartis Vaccines portfolio.
The current year liability is included within Trade and other payables.
L Share capital and share premium account Share premium Ordinary Shares of 25p each account Number m m Share capital authorised At 31 December 2017 10,000,000,000 2,500 At 31 December 2018 10,000,000,000 2,500 Share capital issued and fully paid At 1 January 2017 5,368,316,062 1,342 2,954 Issued under employee share schemes 4,237,758 1 55 Treasury shares transferred to the ESOP Trust 10 At 31 December 2017 5,372,553,820 1,343 3,019 Issued under employee share schemes 6,513,804 2 72 At 31 December 2018 5,379,067,624 1,345 3,091 31 December 31 December 2018 2017 000 000 Number of shares issuable under employee share schemes 56,723 38,647 Number of unissued shares not under option 4,564,209 4,588,799 At 31 December 2018, of the issued share capital, 41,530,909 shares were held in the ESOP Trusts, 414,605,950 shares were held as Treasury shares and 4,922,930,765 shares were in free issue.
All issued shares are fully paid.
The nominal, carrying and market values of the shares held in the ESOP Trusts are disclosed in Note 43, Employee share schemes.
M Retained earnings The loss of GlaxoSmithKline plc for the year was 62 million 2017 9,893 million profit, which after dividends of 3,927 million 2017 3,906 million, gave a retained profit of 18,117 million 2017 5,987 milion.
After the effect of nil Treasury shares transferred to a subsidiary company 2017 581 million, retained earnings at 31 December 2018 stood at 18,117 million 2017 22,106 million, of which 4,096 million was unrealised 2017 4,096 million.
N Group companies See pages 260 to 270 for a complete list of subsidiaries, associates and joint ventures, which forms part of these financial statements.
